CLASS II Device recall · Reported 6 Oct 2021 · FDA Enforcement Report

Vysis CLL FISH Probe Kit with the following components recalled

Abbott Molecular is recalling Vysis CLL FISH Probe Kit with the following components: Vysis LSI p53 SpectrumOrange/ATM, distributed nationwide in the US. The recall was initiated on 4 Aug 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI: (01)00884999042780(10)XXXXX(17)211015(240)04N02-021; US Distribution: Part Number 04N02-021, Lot Numbers 517086, 518656; International Distribution: List/Part Numbers (Lot Number): 04N02-021 (517086, 518656), 04N02-022 (517516, 519303), 05J83-001/Part 32-191025 (517068).
Quantity recalled186 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2576-2021
FDA event ID
88565
Recalling firm
Abbott Molecular, Des Plaines, IL
Classification
Class II
Status
Terminated
Recall initiated
4 Aug 2021
FDA classified
27 Sep 2021
Reported
6 Oct 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

4 Aug 2021Recall initiated by company
27 Sep 2021Classified by FDA+54 days
6 Oct 2021Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Potential for Vysis CLL FISH Probe Kits not detecting 13q deletions in known positive patient samples.

Product as listed by the FDA

Vysis CLL FISH Probe Kit with the following components: Vysis LSI p53 SpectrumOrange/ATM, SpectrumGreen and LSI D13S319, SpectrumOrange/ 13q34, SpectrumAqua/CEP 12 SpectrumGreen Probes

Where it was distributed

Worldwide distribution - US Nationwide distribution in the states of AZ, CA, FL, GA, IL, IN, KY, MI, MN, MA, NC, NJ, NM, NY, OH, PA, TN, TX, UT, VA, VT, WA, WI and the countries of Australia, Belgium, Brazil, Canada, China, Costa Rica, Czech Republic, Estonia, Germany, Hong Kong, Israel, Italy, Kazakhstan, Netherlands, Philippines, Poland, Saudi Arabia, Slovenia, South Africa, South Korea, Spain, United Kingdom, Uruguay.

Nationwide ArizonaCaliforniaFloridaGeorgiaIllinoisIndianaKentuckyMassachusettsMichiganMinnesotaNorth CarolinaNew JerseyNew MexicoNew YorkOhioPennsylvaniaTennesseeTexasUtahVirginia

Questions about this recall

Why was it recalled?

Potential for Vysis CLL FISH Probe Kits not detecting 13q deletions in known positive patient samples.

Which lots are affected?

UDI: (01)00884999042780(10)XXXXX(17)211015(240)04N02-021; US Distribution: Part Number 04N02-021, Lot Numbers 517086, 518656; International Distribution: List/Part Numbers (Lot Number): 04N02-021 (517086, 518656), 04N02-022 (517516, 519303), 05J83-001/Part 32-191025 (517068).

Where was it sold?

Worldwide distribution - US Nationwide distribution in the states of AZ, CA, FL, GA, IL, IN, KY, MI, MN, MA, NC, NJ, NM, NY, OH, PA, TN, TX, UT, VA, VT, WA, WI and the countries of Australia, Belgium, Brazil, Canada, China, Costa Rica, Czech Republic, Estonia, Germany, Hong Kong, Israel, Italy, Kazakhstan, Netherlands, Philippines, Poland, Saudi Arabia, Slovenia, South Africa, South Korea, Spain, United Kingdom, Uruguay.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Abbott Molecular

All 36

Other Other Medical Devices recalls

All 13,908